Mechanistic machine learning links PI3K to Src-inhibitor effects in cardiac fibroblasts
LogiMML, trained on high-content images of human cardiac fibroblasts, predicted that Src inhibition suppresses actin–myosin stress fibers through PI3K signaling. Follow-up PI3K inhibition reduced stress-fiber formation and procollagen I production in the fibroblasts, supporting the proposed pathway mechanism.
Technology: LogiMML, a logic-based mechanistic network coupled to ridge regression
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: LogiMML, trained on high-content images of human cardiac fibroblasts, predicted that Src inhibition suppresses actin–myosin stress fibers through PI3K signaling.
- Still unknown: The validation is in vitro in primary human ventricular cardiac fibroblasts; it supports a pathway contribution to measured cell phenotypes, not therapeutic efficacy in an animal model or patients. The model's PI3K effect is described as partial.
- AI role: LogiMML fitted the relationship between high-content microscopy phenotypes and perturbations to an experimentally informed fibroblast signaling network, then predicted pathway mechanisms for pirfenidone and the Src inhibitor WH-4-023. Researchers tested the PI3K component of the Src-inhibitor prediction with PI3K inhibition in human cardiac fibroblasts.
Evidence sources: https://www.pnas.org/doi/pdf/10.1073/pnas.2303513121
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 23 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.